Last reviewed · How we verify

NCT06921863: DoItAgain

This Study Aims to Quantify Decisional Regret as Well as Quality of Life in Patients With Low- to High-risk Cancer and High Burden of Symptoms Undergoing Radiotherapy Using Established Questionnaires.

Not yet recruiting Last updated 10 April 2025
What this trial tests

trial in Quality of Life (QOL) in 165 participants. Not yet recruiting.

Timeline
1 July 2025
Primary endpoint
1 October 2029
1 October 2032

Quick facts

Lead sponsorUniversity Medical Center Goettingen
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment165
Start date1 July 2025
Primary completion1 October 2029
Estimated completion1 October 2032

Conditions studied

Sponsor

University Medical Center Goettingen

Who can join

18 and older, any sex, with Quality of Life (QOL) or Decision Making ,Shared. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective registry study, patients with low-, intermediate- and high-risk tumor entities as well as patients with high symptom burden of any tumor entity in palliative constellation with indication for radiation treatment are included. This radiation treatment can be applied either as 3D-conformal RT or IGRT. The duration of treatment can range from one day to several weeks. For the primary endpoint as well as the secondary clinical and other exploratory endpoints, the 3 groups will be compared in terms of DR, QoL, toxicities and treatment plan parameters

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Quality of Life (QOL)

Currently open trials in the same condition.

Other University Medical Center Goettingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06921863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing